scholarly journals Factors influencing platelet clumping during peripheral blood hematopoietic stem cell collection

Transfusion ◽  
2017 ◽  
Vol 57 (5) ◽  
pp. 1142-1151
Author(s):  
Gagan Mathur ◽  
Sarah L. Mott ◽  
Laura Collins ◽  
Gail A. Nelson ◽  
C. Michael Knudson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Hematopoietic Stem ◽  
Factors Influencing ◽  
Stem Cell Collection

scholarly journals Stem Cell Mobilization Using Parathyroid Hormone Analog: A Single Institutional Review

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 22-23
Author(s):  
Okechukwu Nwogbo ◽  
Thuy Le ◽  
James Shikle ◽  
Juan Cintron Garcia ◽  
Sheila Tinsley
Keyword(s):  
Stem Cell ◽  
Parathyroid Hormone ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Stem Cell Mobilization ◽  
Hematopoietic Stem ◽  
Peripheral Blood Cd34 ◽  
Cell Mobilization ◽  
Stem Cell Collection ◽  
Poor Mobilizers

Objective: Hematopoietic stem cell mobilization increases the release of immature and maturing hematopoietic cells from the marrow into the blood circulation. For successful hematopoietic stem cell transplantation an adequate number of stem cells must be mobilized and collected. For autologous stem cell transplants, a product bag CD34+ count of > 5.0 x 106 CD34/kg is a target; however, patients have been successfully transplanted with doses as low as 2.0 x 106 CD34/kg. Some patients are "poor mobilizers" and standard protocols do not result in adequate numbers of circulating CD34 cells to collect. Risk factors associated with poor stem cell mobilization include increasing age, underlying diagnosis, low premobilization platelet count, history of increasing cycles, and regimens of chemotherapy. Teriparatide, a parathyroid hormone (PTH) analog has been used in "poor mobilizers." Two patients at our institution received the drug as part of an additional mobilization strategy. Method: Medical records of patients who had stem cell mobilization were reviewed. Two patients who failed routine mobilization protocol received PTH as part of an additional mobilization regimen. Clinical outcomes, collection, and engraftment data were reviewed. Result: Patient 1 had a diagnosis of Hodgkin Lymphoma and failed to mobilize adequately on the first attempt using filgrastim and plerixafor with peripheral blood CD34 counts of 1, 4, and 3 resulting in cancellation of stem cell collection. For the second mobilization attempt, teriparatide was added to the regimen. Peripheral blood CD34 counts improved to 8, 6, and 2 resulting in three collections with a total of 2.23 x 106 CD34/kg for reinfusion. Engraftment data showed 14 days for neutrophils and 17 days for platelets. The patient is 6 months post-transplant with no major morbidities reported, currently in maintenance therapy, and has not recurred. Patient 2 had a diagnosis of multiple myeloma and failed to mobilize on filgrastim and plerixafor with peripheral blood CD34 counts of 2, 2, and 2 resulting in collections with a total of 0.6 x 106 CD34/kg for reinfusion. For the second mobilization attempt, peripheral blood CD34 counts of 2, 2, 2, and 0 resulting in collections with a total of 0.822 x 106 CD34/kg for reinfusion. For the third mobilization attempt, teriparatide was added to the regimen. Peripheral blood CD34 counts improved to 8 and 4 resulting in collections with a total of 1.8 x 106 CD34/kg for reinfusion. Patient expired one month after collection without reinfusion. Conclusion: Two patients who failed standard mobilization for stem cell collection at our institution received teriparatide as part of an additional stem cell mobilization regimen. Adequate doses of stem cell products for transplant were collected. One patient was reinfused and subsequently engrafted appropriately. Teriparatide can be used in the setting of poor mobilization. Disclosures No relevant conflicts of interest to declare.

scholarly journals Factors affecting autologous peripheral blood hematopoietic stem cell collections by large-volume leukapheresis: a single center experience

2011 ◽  
Vol 9 (2) ◽  
pp. 196-200 ◽  
Author(s):  
Araci Massami Sakashita ◽  
Andrea Tiemi Kondo ◽  
Andreza Alice Feitosa Ribeiro ◽  
Andrea Neri Folchini Cipolletta ◽  
Monica Vilela Colesanti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Cell Yield ◽  
Hematopoietic Stem ◽  
Factors Affecting ◽  
Peripheral Blood Cd34 ◽  
Stem Cell Collection

Objective: To evaluate factors affecting peripheral blood hematopoietic stem cell yield in patients undergoing large-volume leukapheresis for autologous peripheral blood stem cell collection. Methods: Data from 304 consecutive autologous peripheral blood stem cell donors mobilized with hematopoietic growth factor (usually G-CSF), associated or not with chemotherapy, at Hospital Israelita Albert Einstein between February 1999 and June 2010 were retrospectively analyzed. The objective was to obtain at least 2 × 106 CD34+ cells/kg of body weight. Pre-mobilization factors analyzed included patient's age, gender and diagnosis. Post mobilization parameters evaluated were pre-apheresis peripheral white blood cell count, immature circulating cell count, mononuclear cell count, peripheral blood CD34+ cell count, platelet count, and hemoglobin level. The effect of pre and post-mobilization factors on hematopoietic stem cell collection yield was investigated using logistic regression analysis (univariate and multivariate approaches). Results: Pre-mobilization factors correlating to poor CD34 + cell yield in univariate analysis were acute myeloid leukemia (p = 0.017) and other hematological diseases (p = 0.023). Significant post-mobilization factors included peripheral blood immature circulating cells (p = 0.001), granulocytes (p = 0.002), hemoglobin level (p = 0.016), and CD34+ cell concentration (p < 0.001) in the first harvesting day. However, according to multivariate analysis, peripheral blood CD34+ cell content (p < 0.001) was the only independent factor that significantly correlated to poor hematopoietic stem cell yield. Conclusion: In this study, peripheral blood CD34+ cell concentration was the only factor significantly correlated to yield in patients submitted to for autologous collection.

Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation

2018 ◽  
Vol 25 (35) ◽  
pp. 4535-4544 ◽  
Author(s):  
Annalisa Ruggeri ◽  
Annalisa Paviglianiti ◽  
Fernanda Volt ◽  
Chantal Kenzey ◽  
Hanadi Rafii ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Circulating Endothelial Cells ◽  
Hematopoietic Stem ◽  
Hematological Diseases

Background: Circulating endothelial cells (CECs), originated form endothelial progenitors (EPCs) are mature cells not associated with vessel walls and detached from the endothelium. Normally, they are present in insignificant amounts in the peripheral blood of healthy individuals. On the other hand, elevated CECs and EPCs levels have been reported in the peripheral blood of patients with different types of cancers and other diseases. Objective: This review aims to provide an overview on the characterization of CECs and EPCs, to describe isolation methods and to identify the potential role of these cells in hematological diseases and hematopoietic stem cell transplantation. Methods: We performed a detailed search of peer-reviewed literature using keywords related to CECs, EPCs, allogeneic hematopoietic stem cell transplantation, and hematological diseases (hemoglobinopathies, hodgkin and non-hodgkin lymphoma, acute leukemia, myeloproliferative syndromes, chronic lymphocytic leukemia). Results: CECs and EPCs are potential biomarkers for several clinical conditions involving endothelial turnover and remodeling, such as in hematological diseases. These cells may be involved in disease progression and in the neoplastic process. Moreover, CECs and EPCs are probably involved in endothelial damage which is a marker of several complications following allogeneic hematopoietic stem cell transplantation. Conclusion: This review provides information about the role of CECs and EPCs in hematological malignancies and shows their implication in predicting disease activity as well as improving HSCT outcomes.

Results of an Autologous Noncryopreserved, Unmanipulated Peripheral Blood Hematopoietic Stem Cell Transplant Program: A Single-Institution, 10-Year Experience

2003 ◽  
Vol 110 (4) ◽  
pp. 179-183 ◽  
Author(s):  
Guillermo J. Ruiz-Argüelles ◽  
David Gómez-Rangel ◽  
Guillermo J. Ruiz-Delgado ◽  
Alejandro Ruiz-Argüelles ◽  
Beatriz Pérez-Romano ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Peripheral Blood ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Single Institution ◽  
Hematopoietic Stem ◽  
Transplant Program
Sign in / Sign up

Export Citation Format

Share Document